Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Atea Pharmaceuticals, Inc. (AVIR) had Income from Continuous Operations of $-135.96M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
-- |
|
$-135.96M |
|
-- |
|
-- |
|
$164.16M |
|
$-164.16M |
|
$29.22M |
|
$-134.94M |
|
$-134.94M |
|
$-135.96M |
|
|
Income from Continuous Operations |
$-135.96M |
$-135.96M |
|
$-135.96M |
|
$-164.16M |
|
$-179.19M |
|
83.39M |
|
83.39M |
|
$-1.63 |
|
$-1.63 |
|
| Balance Sheet Financials | |
$590.46M |
|
$1.29M |
|
$4.51M |
|
$594.97M |
|
$32.38M |
|
-- |
|
$7.40M |
|
$39.78M |
|
$555.19M |
|
$555.19M |
|
$555.19M |
|
83.44M |
|
| Cash Flow Statement Financials | |
$-85.39M |
|
$40.30M |
|
$0.26M |
|
$188.66M |
|
$143.82M |
|
$-44.84M |
|
$49.43M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
18.24 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-85.39M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-24.49% |
|
-24.49% |
|
-22.85% |
|
-24.49% |
|
$6.65 |
|
$-1.02 |
|
$-1.02 |
|